Measures involving grip strength                


Select table page: First Prev 1 - 10 / 30 (30) Next Last
    Access protocols via the Procedure column.
Sort/
Pick
Data set
Procedure / Protocol
Treatment
Phenotype Measure / Variable (click to view)
Panel
No. of Strains
Sex
Age
Sample Size (Avg)
Year
    Crabbe4 grip strength ethanol grip strength test: peak force applied   [g]  grip   19106     baseline    30min after ethanol inbred 21 both 7-12wks N=6 2003
    Crabbe4 grip strength ethanol change in peak force applied (T0-T30) post-injection, grip strength test   [g]  gripEtOHeffect   19108 inbred 21 both 7-12wks N=6 2003
    Crabbe4 grip strength ethanol percent change in average latency to fall post-injection, grip strength test   [%]  pct_gripchange   19109 inbred 21 both 7-12wks N=6 2003
    GMC02 grip strength (none) forelimb grip strength   [g]  front_paws   55111     trial1    trial2    trial3 inbred w/CC8 8 both 8-10wks N=17 2018
    GMC02 grip strength (none) forelimb grip strength, mean   [g]  front_paws_mean   55114 inbred w/CC8 8 both 8-10wks N=17 2018
    GMC02 grip strength (none) forelimb grip strength (mean) normalized to body weight   [ratio]  front_paws_adj   55115 inbred w/CC8 8 both 8-10wks N=17 2018
    GMC02 grip strength (none) forelimb and hindlimb grip strength   [g]  all_paws   55121     trial1    trial2    trial3 inbred w/CC8 8 both 8-10wks N=17 2018
    GMC02 grip strength (none) forelimb and hindlimb grip strength, mean   [g]  all_paws_mean   55124 inbred w/CC8 8 both 8-10wks N=17 2018
    GMC02 grip strength (none) forelimb and hindlimb grip strength (mean) normalized to body weight   [ratio]  all_paws_adj   55125 inbred w/CC8 8 both 8-10wks N=17 2018
    JaxCC1 grip strength (none) forelimb grip strength   [g]  front_paws   89096     trial1    trial2    trial3 CC 18 both 7-9wks N=7 2017
    All boxes             To see more rows use the paging control at top.


  •   Or, add these measures to your collection.
       
  •     no folder
  •     put them in new folder  





Other available data sets:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
ITP1 grip strength
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Interventions vs. controls. UM-HET3 population both various 2004-2024